(c) 2024 PillSync.com

Amlodipine 2.5 MG atorvastatin 40 MG Oral Tablet

1 INDICATIONS AND USAGE Amlodipine and atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine Amlodipine and atorvastatin tablets are a combination of amlodipine besylate, a calcium channel blocker, and atorvastatin calcium, a HMG CoA-reductase inhibitor, indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine is indicated for the treatment of hypertension, to lower blood pressure ( 1.1 ). Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Amlodipine is indicated for the treatment of Coronary Artery Disease ( 1.2 ). Atorvastatin is indicated as an adjunct therapy to diet for prevention of cardiovascular disease ( 1.3 ) and hyperlipidemia ( 1.4 ). 1.1 Hypertension Amlodipine is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine may be used alone or in combination with other antihypertensive agents. 1.2 Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine is indicated for the symptomatic treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction < 40%, amlodipine is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure. Atorvastatin Therapy with HMG CoA-reductase inhibitors (lipid-altering agents) should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease from hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or multiple risk factors for CHD, atorvastatin can be started simultaneously with diet restriction. 1.3 Prevention of Cardiovascular Disease (CVD) in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low high-density lipoprotein cholesterol (HDL-C), or a family history of early coronary heart disease, atorvastatin is indicated to: • Reduce the risk of myocardial infarction (MI) • Reduce the risk of stroke • Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin is indicated to: • Reduce the risk of myocardial infarction • Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin is indicated to: • Reduce the risk of non-fatal myocardial infarction • Reduce the risk of fatal and non-fatal stroke • Reduce the risk for revascularization procedures • Reduce the risk of hospitalization for congestive heart failure (CHF) • Reduce the risk of angina 1.4 Hyperlipidemia Atorvastatin is indicated: • As an adjunct to diet to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B), and triglycerides (TG) levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb) • As an adjunct to diet for the treatment of adult patients with elevated serum TG levels ( Fredrickson Type IV) • For the treatment of adult patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet • To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable • As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: • there is a positive family history of premature CVD or • two or more other CVD risk factors are present in the pediatric patient 1.5 Limitations of Use Atorvastatin has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V).

Mylan Pharmaceuticals Inc.


4 years ago OVAL WHITE M AA3 Amlodipine 2.5 MG  atorvastatin 40 MG Oral Tablet

OVAL WHITE M AA3

16 HOW SUPPLIED/STORAGE AND HANDLING

AMLODIPINE AND ATORVASTATIN Tablets, USP are available containing 5 mg or 10 mg amlodipine equivalent to 6.94 mg or 13.88 mg amlodipine besylate USP, respectively, and 10 mg, 20 mg, 40 mg or 80 mg atorvastatin equivalent to 10.844 mg, 21.688 mg, 43.376 mg or 86.751 mg atorvastatin calcium USP, respectively, providing for the following combinations: 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg. The 5 mg/10 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with M on one side of the tablet and AA4 on the other side. They are available as follows: NDC 0378-4513-93 bottles of 30 tablets The 5 mg/20 mg tablets are white to off-white, film-coated, round, unscored tablets debossed with M on one side of the tablet and AA5 on the other side. They are available as follows: NDC 0378-4514-93 bottles of 30 tablets The 5 mg/40 mg tablets are white to off-white, film-coated, capsule shaped, unscored tablets debossed with M on one side of the tablet and AA6 on the other side. They are available as follows: NDC 0378-4515-93 bottles of 30 tablets The 5 mg/80 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with M on one side of the tablet and AA7 on the other side. They are available as follows: NDC 0378-4516-93 bottles of 30 tablets The 10 mg/10 mg tablets are blue, film-coated, barrel shaped, unscored tablets debossed with M on one side of the tablet and AA8 on the other side. They are available as follows: NDC 0378-4517-93 bottles of 30 tablets The 10 mg/20 mg tablets are blue, film-coated, oval, unscored tablets debossed with M on one side of the tablet and AA9 on the other side. They are available as follows: NDC 0378-4518-93 bottles of 30 tablets The 10 mg/40 mg tablets are blue, film-coated, round, unscored tablets debossed with M on one side of the tablet and AA10 on the other side. They are available as follows: NDC 0378-4519-93 bottles of 30 tablets The 10 mg/80 mg tablets are blue, film-coated, capsule shaped, unscored tablets debossed with M on one side of the tablet and AA11 on the other side. They are available as follows: NDC 0378-4520-93 bottles of 30 tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.


More pills like OVAL M AA3












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site